Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells

2.50
Hdl Handle:
http://hdl.handle.net/2436/620384
Title:
Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells
Authors:
Wang, Zhipeng; Tan, Jiao; McConville, Christopher; Kannappan, Vinodh; Tawari Patricia Erebi; Brown, James; Ding, Jin; Armesilla, Angel L.; Irache, Juan M.; Mei, Qi-Bing; Tan, Yuhuan; Liu, Ying; Jiang, Wenguo; Bian, Xiuwu; Wang, Weiguang
Abstract:
Disulfiram (DS), an anti-alcoholism drug, shows very strong cytotoxicity in many cancer types. However its clinical application in cancer treatment is limited by the very short half-life in the bloodstream. In this study, we developed a poly lactic-co-glycolic acid (PLGA)-encapsulated DS protecting DS from the degradation in the bloodstream. The newly developed DS-PLGA was characterized. The DS-PLGA has very satisfactory encapsulation efficiency, drug-loading content and controlled release rate in vitro. PLGA encapsulation extended the half-life of DS from shorter than 2 minutes to 7 hours in serum. In combination with copper, DS-PLGA significantly inhibited the liver cancer stem cell population. CI-isobologram showed a remarkable synergistic cytotoxicity between DS-PLGA and 5-FU or sorafenib. It also demonstrated very promising anticancer efficacy and antimetastatic effect in liver cancer mouse model. Both DS and PLGA are FDA approved products for clinical application. Our study may lead to repositioning of DS into liver cancer treatment.
Publisher:
Elsevier
Journal:
Nanomedicine: Nanotechnology, Biology and Medicine Volume 13, Issue 2, February 2017, Pages 641–657
Issue Date:
Feb-2017
URI:
http://hdl.handle.net/2436/620384
DOI:
10.1016/j.nano.2016.08.001
Additional Links:
http://www.sciencedirect.com/science/article/pii/S1549963416301083
Type:
Article
Language:
en
ISSN:
1549-9634
Appears in Collections:
FSE

Full metadata record

DC FieldValue Language
dc.contributor.authorWang, Zhipengen
dc.contributor.authorTan, Jiaoen
dc.contributor.authorMcConville, Christopheren
dc.contributor.authorKannappan, Vinodhen
dc.contributor.authorTawari Patricia Erebien
dc.contributor.authorBrown, Jamesen
dc.contributor.authorDing, Jinen
dc.contributor.authorArmesilla, Angel L.en
dc.contributor.authorIrache, Juan M.en
dc.contributor.authorMei, Qi-Bingen
dc.contributor.authorTan, Yuhuanen
dc.contributor.authorLiu, Yingen
dc.contributor.authorJiang, Wenguoen
dc.contributor.authorBian, Xiuwuen
dc.contributor.authorWang, Weiguangen
dc.date.accessioned2017-02-21T14:44:49Z-
dc.date.available2017-02-21T14:44:49Z-
dc.date.issued2017-02-
dc.identifier.issn1549-9634en
dc.identifier.doi10.1016/j.nano.2016.08.001-
dc.identifier.urihttp://hdl.handle.net/2436/620384-
dc.description.abstractDisulfiram (DS), an anti-alcoholism drug, shows very strong cytotoxicity in many cancer types. However its clinical application in cancer treatment is limited by the very short half-life in the bloodstream. In this study, we developed a poly lactic-co-glycolic acid (PLGA)-encapsulated DS protecting DS from the degradation in the bloodstream. The newly developed DS-PLGA was characterized. The DS-PLGA has very satisfactory encapsulation efficiency, drug-loading content and controlled release rate in vitro. PLGA encapsulation extended the half-life of DS from shorter than 2 minutes to 7 hours in serum. In combination with copper, DS-PLGA significantly inhibited the liver cancer stem cell population. CI-isobologram showed a remarkable synergistic cytotoxicity between DS-PLGA and 5-FU or sorafenib. It also demonstrated very promising anticancer efficacy and antimetastatic effect in liver cancer mouse model. Both DS and PLGA are FDA approved products for clinical application. Our study may lead to repositioning of DS into liver cancer treatment.en
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttp://www.sciencedirect.com/science/article/pii/S1549963416301083en
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectDisulfiramen
dc.subjectPLGAen
dc.subjectLiver canceren
dc.subjectCancer stem cellsen
dc.subjectDrug repositioningen
dc.subjectNano-technologyen
dc.subjectDrug deliveryen
dc.titlePoly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cellsen
dc.typeArticleen
dc.identifier.journalNanomedicine: Nanotechnology, Biology and Medicine Volume 13, Issue 2, February 2017, Pages 641–657en
dc.date.accepted2016-08-
rioxxterms.funderEU Commissionen
rioxxterms.identifier.projectUoW210217WWen
rioxxterms.versionAMen
rioxxterms.licenseref.urihttps://creativecommons.org/CC BY-NC-ND 4.0en
rioxxterms.licenseref.startdate2017-02-21en
This item is licensed under a Creative Commons License
Creative Commons
All Items in WIRE are protected by copyright, with all rights reserved, unless otherwise indicated.